IIT-Chhabra-EMBRACE-MM: A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) after BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Protocol No
IIT-CHHABRA-EMBRACE-MM
Principal Investigator
Meera Mohan
Phase
II
Summary
The purpose of this study is to test the safety and effectiveness of a potential new treatment called Belantamab Mafodotin for subjects who have previously received at least three treatments, including CAR-T therapy.
Description
Maintenance post CAR-T for MM
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL